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In reference to Figure 4D, the drug quercetin is clearly cytotoxic as
a single agent in the ALL-SIL cell line, but its effect in combination
with dexamethasone (DEX) is not synergistic as originally quoted.
Rather, the combination of quercetin and DEX resulted in a small,
though non-significant reduction in cytotoxicity. This is in
contrast to resveratrol (Figure 4E), which demonstrated synergistic
cytotoxicity in combination with DEX. This difference in the two
agents is reflected in their connectivity map (CMAP) enrichment
scores in Table 3, with quercetin showing a positive enrichment in
contrast to the negative scores for resveratrol, LY-294002 and
rapamycin. Both quercetin and resveratrol are polyphenols that
activate the key metabolic regulator AMPK, but the results suggest
that they are mechanistically different and are unlikely to be
equally efficacious in combinatorial therapy with glucocorticoids
in T-cell acute lymphoblastic leukaemia (T-ALL). Figure 4D and
Table 3 from the original paper are reproduced for reference,
below.
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Figure 4 Synergy of CMAP-identified drugs with DEX in T-ALL cell lines.
Graphs show cell survival following 48h incubation. Comparisons were
made in each data set to the respective control condition, which was set to
100%. Vehicle control (C) and the following drug treatments were
analysed: (D) 10mM (Q10), 25mM (Q25) quercetin and 1mM DEX (D1) in
ALL-SIL.
Table 3 CMAP drugs significantly associated with MPRED- and DEX-resistance gene signatures in T-ALL cell lines
MPRED DEX
Drug Mechanism of action Enrichment P-value Drug Mechanism of action Enrichment P-value
LY-294002 AKT/PI3K inhibitor 0.507 0.0001 Rapamycin mTOR inhibitor 0.653 o0.0001
Trichostatin A HDAC inhibitor 0.423 0.018 Geldenamycin HSP90 inhibitor 0.655 0.004
Carbamazepine Antiepileptic 0.792 0.020 LY-294002 AKT/PI3K inhibitor 0.397 0.005
W-13 Calmodulin antagonist 0.903 0.021 Sodium phenylbutyrate HDAC inhibitor 0.564 0.014
Blebbistatin Myosin II inhibitor 0.896 0.023 Quercetin ROS scavenger/antioxidant 0.903 0.019
Wortmannin AKT/PI3K inhibitor 0.497 0.024 Resveratrol ROS scavenger/antioxidant 0.630 0.020
Benserazide Amino-acid decarboxylase inhibitor 0.885 0.028 Cobalt chloride Hypoxia mimetic 0.742 0.037
Rapamycin mTOR inhibitor 0.441 0.031 Fludrocortisone Steroid 0.857 0.042
Indomethacin Cyclo-oxygenase inhibitor 0.662 0.031 Deferoxamine Hypoxia mimetic 0.717 0.049
Quercetin ROS scavenger/antioxidant 0.876 0.033
Y-27632 Rho-kinase inhibitor 0.872 0.036
Tamoxifen Oestrogen-receptor blocker 0.740 0.039
Resveratrol ROS scavenger/antioxidant 0.583 0.040
Data indicate the CMAP-calculated enrichment score and permuted P-value for association with GC expression profiles.
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